Why Trump Is Pushing Psychedelics To Treat Mental Illness

• Three drug companies, including public entity Compass Pathways (CMPS), received priority FDA review vouchers for psilocybin and methylone (MDMA-like) treatments, leading to a rally in psychedelic drug stocks.
• The executive order highlights the potential of psychedelic drugs like psilocybin (for depression), MDMA (for PTSD), and ibogaine (for substance abuse) based on clinical studies.
• While veterans shared positive experiences with MDMA therapy, scientists express concern about rushing the review process, particularly for ibogaine due to limited clinical data and cardiovascular risks, and note the FDA previously rejected MDMA-assisted therapy for PTSD in 2024.
• The expedited FDA approval timeline (1-2 months with a voucher vs. 10 months without) and the timing of the executive order are viewed by some as politically motivated, aiming to win back lost supporters.

The Trump administration's executive order to fast-track FDA approval for psychedelic drugs to treat serious mental illnesses has created a significant tailwind for the nascent industry. This policy shift, a reversal from previous stances, aims to address mental health crises but also raises questions about scientific rigor and political motivations, despite positive testimonials from veterans who have undergone psychedelic treatments.